stockrowLeMaitre Vascular, Inc.
LMAT Healthcare Medical Instruments & Supplies
LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024.
- Revenue
- +11.3%
- EPS
- −14.3%
- Free cash flow
- −25.8%
- Total debt
- +0.53%
Quarter to September 2026, against a year earlier
Follow LMAT
Alert me
LeMaitre Vascular, Inc. (LMAT) Return on equity
LeMaitre Vascular, Inc.'s return on equity over the twelve months to 30 September 2026 was 15.6%, down 0.2 percentage points from fiscal 2025 (15.8%). Over the past ten years it has ranged from 7.90% (fiscal 2022) to 19.1% (fiscal 2018); the current reading is higher than 82% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 15.8% | 1.93 |
| FY2024 | 13.9% | 3.23 |
| FY2023 | 10.6% | 2.74 |
| FY2022 | 7.90% | (4.71) |
| FY2021 | 12.6% | (0.62) |
| FY2020 | 13.2% | 0.35 |
| FY2019 | 12.9% | (6.24) |
| FY2018 | 19.1% | 1.71 |
| FY2017 | 17.4% | 4.60 |
| FY2016 | 12.8% | 2.19 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LMAT LeMaitre Vascular, Inc. | 15.6% |
| STVN Stevanato Group S.p.A. compare | 9.22% |
| ATRC AtriCure, Inc. compare | 2.95% |
| WRBY Warby Parker Inc. compare | 1.93% |
| STAA STAAR Surgical Company compare | 0.15% |
| AZTA Azenta, Inc. compare | −7.72% |
| XRAY DENTSPLY SIRONA Inc. compare | −8.55% |
| PLSE Pulse Biosciences, Inc compare | −60.7% |
| KMTS Kestra Medical Technologies, Ltd. compare | −73.7% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on LMAT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement